deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders

... allowed the deCODE chemistry team to identify a novel binding site for allosteric modulators in the PDE4 regulatory domain. Binding of an allosteric modulator at that site is non-competitive with cAMP. DG071 has been shown ...

Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting

... Colorado. The poster presentation entitled, "Trodusquemine (MSI-1436), An allosteric Inhibitor of Protein Tyrosine Phosphatase 1B," concluded that MSI-1436 is ... inhibitor of PTP-1B in clinical stage development. It is the allosteric nature of MSI-1436 and its ability to reversibly inhibit PTP-1B that is ...

Xytis Names Gordon H. Busenbark as Chief Financial Officer

... partnering interest in two of our pre-clinical programs; positive allosteric modulators of GABA-A receptor and of alpha-7 nicotinic acetylcholine ... of proprietary preclinical compounds that are novel, highly selective allosteric modulators of nicotinic acetylcholine receptors (nAChRs), GABA-A receptors ...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

... granisetron, were reported. Competitive versus allosteric interactions between these agents and the 5-HT(3) ... dual action suggesting competitive and allosteric interactions with the 5-HT3 receptor. In ... competitive antagonism. The Aloxi allosteric interaction with the 5-HT3 receptor indicates ...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

... granisetron, were reported. Competitive versus allosteric interactions between these agents and the 5-HT(3) ... dual action suggesting competitive and allosteric interactions with the 5-HT3 receptor. In ... competitive antagonism. The Aloxi allosteric interaction with the 5-HT3 receptor indicates ...

Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

... type 2. Addex's competence in drug development and its expertise in allosteric modulation were recognised through the establishment of a partnership for co-development of mGluR2 positive allosteric modulators for anxiety and schizophrenia with Johnson & Johnson in ...

Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine

... a Phase IIa study in anxiety. ADX10059 is a potent, selective, negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5 NAM). ... disease. Addex's competence in drug development and its expertise in allosteric modulation were recognised in a collaboration established in 2004 with ...

Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting

... The oral presentation was given by Christopher D. Roberts, Ph.D., Director of Medicinal Chemistry at Genelabs, entitled "GL59728: A Potent allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase with Excellent Pharmacokinetic Properties." GL59728 is one of a number of non-nucleoside HCV ...

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

... positive top-line results from its first phase II clinical trial of EVT 201 in patients with chronic primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blinded, placebo controlled cross-over study design of two doses of EVT 201 (1.5mg and ...

Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

... patients with major depressive disorder (MDD) and was at least as efficacious in long-term treatment(1). The study directly compared Cipralex(R) (an allosteric serotonin reuptake inhibitor - ASRI) to duloxetine (the most recently introduced serotonin and noradrenaline reuptake inhibitor - SNRI) and ...

Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...

... positive top-line results from its first phase II clinical trial of EVT 201 in patients with chronic primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blinded, placebo controlled cross-over study design of two doses of EVT 201 (1.5mg and ...